Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 1 19Phase NA 15Phase 1/2 13Phase 3 12Phase 4 4Phase 2/3 3Phase EARLY_PHASE1 2

Status

Completed 5Recruiting 3Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 75Other hematologic neoplasm 32Lymphoid 27Genitourinary 27Gynecologic 25Thoracic 23Head & Neck 20Breast 17Plasma cell 9Dermatologic 9CNS 8Tumor-Agnostic 5Myeloid 5Endocrine 5Other 4Sarcoma 3Other solid neoplasm 3NET 3Classical hematology 3

Conditions

Neuroendocrine Tumors 2Neoplasm Metastasis 1Gastroenteropancreatic Neuroendocrine Tumors 1Adenoma, Islet Cell 1

Interventions

Everolimus 2Somatostatin 1Sirolimus 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × NET × Clear all
NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT06943755 2026-04-17

STELLAR-311

Exelixis

Phase 2/3 Recruiting
440 enrolled
EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT06855095 2025-03-03

ATSA

The Netherlands Cancer Institute

Phase 2/3 Recruiting
39 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡